Posts

ORNL wins five Federal Laboratory Consortium awards

Researchers, staff members and licensees from the Department of Energy’s Oak Rid...

Why cancer immunotherapies don’t work for everyone

A multi-institutional study co-authored by University of Texas at Arlington scie...

Salk Institute Professor Ronald Evans honored with Japa...

LA JOLLA (January 22, 2024)—Salk Professor Ronald Evans has been named the 2024 ...

Lights, detector, action!

Kyoto, Japan — Our understanding of the world relies greatly on our knowledge of...

Novel macrolide–DEL-1 axis drives bone regeneration in ...

Niigata, Japan – Scientists from Niigata University discover macrolide-based mol...

Recovering lossless propagation: HKU physicists overcom...

A collaborative research team co-led by Professor Shuang ZHANG, the Interim Head...

A pathway to environmental restoration: Sustainable str...

The Fukushima Daiichi nuclear disaster, triggered by the earthquake and tsunami ...

Avoiding cloudy messaging: Vape prevention campaigns fa...

Flinders University researchers say that cohesive and collaborative action from ...

HKU Common Core and HKUMed teams win one Silver and one...

Two innovative teaching and learning projects led by The University of Hong Kong...

Surrozen Abandons IBD Treatment SZN-1326

Surrozen finds itself at a crossroads in its pursuit of a treatment for inflamma...

AM-Pharma Begins Phase 2 Trial of Ilofotase Alfa For Re...

AM-Pharma B.V. announced that the first individuals have been given treatment in...

Sun and Taro reach an agreement on  $348M buyout after ...

Sun Pharmaceutical and Taro Pharmaceutical have formally announced their merger ...

Balversa Receives FDA Approval for Bladder Cancer Treat...

Balversa (erdafitinib) has received complete approval from the FDA, permitting i...

Over 200 layoffs planned by Lonza at clinical productio...

The Swiss Contract Development and Manufacturing Organization (CDMO) is now sign...

Bayer in artificial intelligence: theme innovation stra...

How many patents did Bayer submit related to artificial intelligence last quarte...

Genentech signs nanoparticle deal worth up to $644m wit...

Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therap...